|Articles|June 1, 2008

Pharmaceutical Executive

  • Pharmaceutical Executive-06-01-2008
  • Volume 0
  • Issue 0

Hoji Alimi, Oculus Innovative Sciences

S

Hoji Alimi

Founder, President, and CEO, Oculus Innovative Sciences

SECRET TO HIS SUCCESS: Conviction

FAVE MOVIE: Gladiator—"It shows the importance of the greater good"

Hoji Alimi, whose father was a general in the Iranian army, was exiled as a teen when the Shah was desposed. "Life wasn't handed to me on a silver platter," he says. He became a microbiologist, honing his skills at AVE (bought by Medtronic) as a biologist and toxicologist. While pursuing his master's degree, he found a promising cancer compound—but his professor refused the data, which contradicted other findings. Alimi used it to found Micromet Labs.

Hoji Alimi

"My wife and I wanted to buy a house," he says. "I told her, we could buy it and that would be our life—or we could take this opportunity. She said to go for it or I'd regret it for the rest of my life."

Another compound soon caught Alimi's attention. An investor sent him a liquid shown to induce rapid wound healing. "For four years, I worked by day at Micromet and then would stay up trying to reformulate the product to be stable. People asked when I was going to give up."

But Alimi didn't give up, and has since shown Microcyn, as trademarked, to be more effective than levofloxicin at helping burn patients leave the hospital, and is effective against drug-resistant bacteria. Now this wound care solution is marketed around the world—and just completed Phase II trials in the US.

Articles in this issue

over 18 years ago

Mary Szela, Abbott

over 18 years ago

Mightier Than the Sword

over 18 years ago

Eric Floyd, Cephalon

over 18 years ago

Nancy Phelan, Wyeth

over 18 years ago

Tightening the Chain

over 18 years ago

Kurt Graves, Vertex

over 18 years ago

Wendy Niebler, Shire

over 18 years ago

Perfectly Imperfect

Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.